Company news

Travere Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2026

Travere Therapeutics Reports Third Quarter 2026 Financial Results

November 2, 2026

Travere Therapeutics to Report Third Quarter 2026 Financial Results

October 26, 2026

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

October 23, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 12, 2026

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

October 2, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

September 23, 2026

Travere Therapeutics Announces Planned Chief Executive Officer Transition

September 21, 2026

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

September 17, 2026

Travere Therapeutics Reports Second Quarter 2026 Financial Results

August 4, 2026

Travere Therapeutics to Report Second Quarter 2026 Financial Results

July 28, 2026

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

June 16, 2026

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

June 3, 2026

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

June 2, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

May 27, 2026

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 6, 2026

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 5, 2026

Travere Therapeutics Reports First Quarter 2026 Financial Results

May 3, 2026

Travere Therapeutics to Report First Quarter 2026 Financial Results

April 27, 2026

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

April 12, 2026

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

February 19, 2026

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

February 4, 2026

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

January 13, 2026

Travere Therapeutics Provides Corporate Update and 2026 Outlook

January 11, 2026

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

November 5, 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2025

Travere Therapeutics Reports Third Quarter 2025 Financial Results

October 29, 2025

Travere Therapeutics to Report Third Quarter 2025 Financial Results

October 22, 2025

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

October 16, 2025

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

September 25, 2025

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

September 9, 2025

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

September 2, 2025

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

August 26, 2025

Travere Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025

Travere Therapeutics to Report Second Quarter 2025 Financial Results

July 29, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

June 10, 2025

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

June 9, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

June 2, 2025

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

May 22, 2025

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

May 14, 2025

Travere Therapeutics Reports First Quarter 2025 Financial Results

April 30, 2025

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

April 28, 2025

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

April 28, 2025

Travere Therapeutics to Report First Quarter 2025 Financial Results

April 23, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

March 30, 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

March 16, 2025

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

February 19, 2025

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

February 12, 2025

Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.